Idactamab

伊达妥单抗

Report date: 2025/01/03 20:01:02

Base Information

Drug NameIdactamab
Drug Alias NameMEDI-7247INT-001
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionImmunomodulatorsNeutral amino acid transporter B(0) inhibitors
TargetsNeutral amino acid transporter B(0)
Therapy Area/IndicationsProstatic Neoplasms, Castration-ResistantSmall Cell Lung CarcinomaCarcinoma, Non-Small-Cell Lung +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesFrance +[4] 
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAstrazeneca PlcMedimmune Llc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesMedimmune Llc
Active IndicationsN/A
Inactive IndicationsProstatic Neoplasms, Castration-ResistantSmall Cell Lung CarcinomaCarcinoma, Non-Small-Cell Lung +[9] 

Other Information

ATC CodeN/A
Related LinksN/A